Briefing Summary: US FDA Posts Advisory Committee Materials for Regeneron Pharmaceuticals’ and Sanofi Aventis’ PCSK9 Inhibitor, PRALUENT (Alirocumab), for High Cholesterol – JUN 9, 2015 (EMDAC)

The US FDA has posted details, including company and FDA Briefing Materials, for the Tuesday, June 9, 2015 Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) meeting. The Committee will discuss the safety and efficacy of PRALUENT (Alirocumab) for injection, submitted by Sanofi Aventis, U.S. (Sanofi) and Regeneron Pharmaceuticals, Inc. (Regeneron) for the treatment of high cholesterol (BLA Number 125559).

See the SAC Tracker report